Market news

In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...

Madison Investments, an investment advisor, released its second-quarter 2026 investor letter for the “Madison Mid Cap Fund”. You can download a copy of the letter here. U.S. stock market indices posted their strongest second-quarter performance since 2020, driven largely by enthusiasm for Artificial Intelligence. Nine of the ten largest companies in the Russell Midcap Index […]

WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

AUSTIN, Texas, September 16, 2026--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening tool available in the U.S. today, the Onclarity™ HPV Self-Collection Kit, tested with the BD Onclarity™ HPV Assay.1 The new diagnostic-led solution supports health plans as they expand access to cervical cancer screening and make it easier for eligible members to complete rec

Waters Corporation (NYSE: WAT) today announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, which uniquely combines exceptional spectral resolution and sensitivity with industry-leading standardization and ease-of-use features, making the power of advanced flow cytometry more accessible to researchers in academia and pharmaceutical settings, as well as in contract research organization (CRO) labs.

Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on Wednesday, September 23, 2026, at 12:00 PM BST (GMT+1) / 7:00 AM Eastern Time.

Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Waters Corporation recently announced that Senior Vice President of the Waters Analytical Sciences Division, Robert L. Carpio III, resigned in August 2026, with Tina Wu, previously head of the Materials Sciences Division and President, China, stepping into the role after more than two decades of global leadership experience at DuPont. Around the same time, Waters reported very large year-over-year revenue growth in the second quarter of 2026 and raised its full-year guidance, underlining the...

Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

WEST CHESTER, Ohio, August 27, 2026--LetsGetChecked now offers the most comprehensive FDA-cleared at-home HPV screening tool available in the U.S.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.

Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9th, 2026, at 10:15 AM Eastern Time.

Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)

Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The

Detailed price information for Waters Corp (WAT-N) from The Globe and Mail including charting and trades.

Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business reve

Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring other companies supplying the tools...

WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.

Detailed price information for Waters Corp (WAT-N) from The Globe and Mail including charting and trades.

Moby summary of Waters Corporation's Q2 2026 earnings call

Waters Corporation (NYSE:WAT) reported second-quarter 2026 results that came in ahead of Wall Street expectations, supported by strong organic growth across its pharmaceutical and industrial businesses. The analytical instruments and diagnostics company’s shares were little changed in pre-market trading, edging up 0.

Scientific instruments company Waters Corporation (NYSE:WAT) announced better-than-expected revenue in Q2 CY2026, with sales up 113% year on year to $1.65 billion. The company expects next quarter’s revenue to be around $1.75 billion, close to analysts’ estimates. Its non-GAAP profit of $3.05 per share was 1.4% above analysts’ consensus estimates.

Waters Corporation (NYSE: WAT),today announced its financial results for the second quarter of 2026.

Detailed price information for Waters Corp (WAT-N) from The Globe and Mail including charting and trades.

Waters (WAT) delivered earnings and revenue surprises of +1.33% and +1.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instruments company Waters Corporation (NYSE:WAT) will be reporting results this Tuesday before the bell. Here’s what to expect.

Waters Corporation (WAT) Q2 Earnings: What To Expect

Detailed price information for Waters Corp (WAT-N) from The Globe and Mail including charting and trades.

Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Waters (WAT) is back on investor radars after recent trading highlighted its role in analytical instruments and software used across pharmaceuticals, chemicals, and environmental testing. This has prompted a closer look at its valuation and fundamentals. See our latest analysis for Waters. At a share price of US$374.68, Waters has seen short term volatility, with the share price slipping 2.02% over the last day but gaining 24.98% over 90 days. The 1 year total shareholder return of 23.68%...

Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Waters Corporation (NYSE:WAT) and its peers.

Waters Corporation will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.